Life Sciences

Sunovion Pharmaceuticals has received approval from the U.S. Food and Drug Administration for its novel drug Latuda, for the treatment of schizophrenia in kids ages 13 to 17.

Zebra Biologics Inc., a Concord-based emerging pre-clinical biotechnology company, is collaborating with Worcester global biopharma AbbVie to discover agonist antibody therapies for inflammatory diseases.

Marlborough drugmaker RXi Pharmaceuticals Corp. announced Thursday it has completed a $11.5-million public offering of its stock.

Sunovion announced Wednesday it has entered into an exclusive U.S. license agreement with Swiss drugmaker Novartis for three of its lung disease medicines.

Massachusetts will anchor the northeastern confluence of the first American biopharmaceutical manufacturing innovation institute, and two Worcester institutions will be closely involved.

Holliston life sciences manufacturer Harvard Bioscience announced Friday it sold its Germany liquid handling product maker for $1.7 million.

Marlborough drugmaker Sunovion Pharmaceuticals announced Thursday that clinical tests for its new drug to treat adolescents with schizophrenia is showing positive signs.

The University of Massachusetts Medical School is now home to two high-resolution microscopes that businesses will be able to use for research.

Framingham medical device maker Arch Therapeutics reported it met the objectives of its clinical study for a device that treats bleeding skin lesions.

Sterling Manufacturing is a vertically integrated, injection molding solutions maker serving the healthcare, aviation, defense and commercial industries.